Patients with TP53 and/or KRAS mutations were sensitive to PD‐1 blockade.29 Researchers further analyzed the relationship between somatic mutations and the effect of anti‐PD‐1/PD‐L1/CTLA‐4 or other antibodies,30 and the results indicated that cancers with specific variations were sensitive to PD‐1 antibodies, while the tumors with EGFR, MDM2, MDM4 and DNMT3A abnormalities were less responsive to PD‐1 antibodies. The gene discussed is CTLA4; the disease is cancer.